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Abstract: As one of Gavi, the Vaccine Alliance (previously the Global Alliance for Vaccines and
Immunization), graduating countries, Indonesia is still eligible to access Gavi price for PCV13,
PCV10 A and B. This study aims to estimate the economic impact of switch from the existing
product/presentation of PCV (single-dose of PCV13) to the new product/presentation of PCV
(multi-dose of PCV13, PCV10 A and B) since PCV is one of the most expensive vaccines in the Expanded
Program on Immunization (EPI) schedule. Assuming that Gavi-Advance Market Commitment (AMC)
price for all PCVs can be accessed in 2021, the use of multi-dose PCV13, PCV10 A and PCV10 B with
Gavi-AMC price in 2021–2024 were considered as respective scenarios. The result showed that the
scenario assuming the use of single-dose of PCV13 with contract price in 2019–2020 that would be
switched into multi-dose of PCV10 B with Gavi-AMC price in 2021–2024 resulted in the highest
potential saving, compared with other scenarios. Our analysis suggests an economic advantage to
switch from single-dose into a multi-dose presentation. Vaccination coverage, vaccine price, vaccine
wastage and additional Gavi-AMC vaccine costs were considered to be the most influential parameter
affecting the savings in all scenarios. Applying the effectiveness of PCV13 and PCV10 A on reducing
the risk for invasive pneumococcal disease (IPD), potential averted incidence of IPD in children under
one year of age during 2019–2024 would be 246,164 and 105,587 in both scenarios. Despite the result
confirmed that PCV13 may provide an additional benefit, a more comprehensive economic evaluation
study is required to investigate further the comparison of cost-effectiveness values among all PCVs
in Indonesia.
Keywords: Gavi-AMC; potential saving; vaccine price; multi-dose; cold chain
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1. Introduction
Streptococcus pneumoniae causes a variety of diseases, such as pneumonia, acute otitis media (AOM)
and invasive pneumococcal disease (IPD) [1]. The World Health Organization (WHO) estimated that
5.8 million children under five years old die every year, with 300,000 being estimated to be caused
by pneumococcal infections [2]. The incidence of IPD varies by country, which has been reported
to be 5-416/100,000 in developing countries [3]. Approximately 75% of IPD cases occur in children
under two years old [3]. In Indonesia, pneumococcal disease is the major cause of infant mortality [4].
The United Nations Children’s Fund (UNICEF) highlighted that 71 children in Indonesia are infected
with pneumonia every hour [5]. To decrease morbidity and mortality rate of pneumonia in children
under five years old, the government of Indonesia has tried to intensify prevention and control
strategies, such as through the case management of pneumonia in the community, health centers
and hospitals, exclusive breastfeeding for the first six months of life, improvement of nutrition and
prevention of low birth weight [6]. Nevertheless, the number of outpatients, hospitalized and fatal
cases due to pneumonia remains high.
Infant vaccination is considered to be the most effective way to prevent infections and reduce
the burden, mortality and sequelae in children (direct effect) and adult populations (indirect effect).
Three pneumococcal conjugate vaccines (PCVs) have been licensed to immunize children against
pneumococcal disease: (i) a 7-valent PCV (PCV7), which is no longer available; (ii) a 10-valent
PCV (PCV10); and (iii) a 13-valent PCV (PCV13) [7]. PCV10 and PCV13 differ in the number of
serotypes they contain, the amount of capsular polysaccharide antigen per serotype, the carrier
proteins these antigens are conjugated to, and the method used for conjugation [8–10]. In particular,
both PCV10 and PCV13 have proven to be effective in preventing pneumococcal diseases. The vaccine
manufacturers recommend that infants who receive the first dose of one of the vaccines should
complete the immunization course with the same vaccine [8,9]. Recently, the WHO has revisited this
recommendation, now specifically mentioning that if this is not possible, the other PCV should be
used to complete the regimen [2]. Several countries have switched from PCV13 to PCV10 (or vice
versa) in their infant immunization programs [11–18]. Other countries have considered switching
between PCVs as part of their immunization program based on local epidemiology and programmatic
factors [2,19].
Epidemiological surveillance of S. pneumoniae serotype carriage in developing countries is
important to implement appropriate vaccination strategies. A previous study by Hadinegoro et al.
confirmed that serotypes 6A/B (22% of pneumococcal strains) were the most frequent serotypes
found in Indonesia [20]. Another study by Dunne et al. mentioned that serotypes 15B/C, 23F, NT2
(a non-capsulated lineage), 19F and 6A were the most common serotypes identified [21]. Overall,
approximately 46.3% and 32.3% of pneumococcal infections belonged to PCV13 and PCV10 serotypes,
respectively [21]. Following the results of these studies, the government of Indonesia has initiated
to introduce PCV13 in 2017 in two selected districts (West and East Lombok), which represented
districts in a province with the highest percentage of pneumonia cases in children under five years
old in Indonesia [4,22]. As one of Gavi, the Vaccine Alliance (previously the Global Alliance for
Vaccines and Immunization), graduating countries, Indonesia is still eligible to access Gavi prices for
both PCV10 and PCV13 [23]. According to Gavi’s latest report, there are five products/presentations
of PCVs that can be procured via UNICEF Supply Division (SD) in 2020 [24]. These vaccines are
single-dose (one dose/vial) and multi-dose (four doses/vial) PCV13, multi-dose (four doses/vial) PCV10
A, single-dose (one dose/vial) and multi-dose (five doses/vial) PCV10 B as the newest vaccine [9].
In comparison with PCV10 A (serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F) and B (serotypes 1, 5,
6A, 6B, 7F, 9V, 14, 19A, 19F and 23F), PCV13 contains three additional antigens (serotypes 3, 6A and
19A). More detailed information can be seen in Table 1.
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Table 1. Characteristics of pneumococcal conjugate vaccines (PCVs; PCV13, PCV10 A and PCV10 B).
Characteristics
PCV13 PCV10 A PCV10 B
1 Dose/Vial 4 Dose/Vial 4 Dose/Vial 1 Dose/Vial 5 Dose/Vial
Serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F, 23F 1, 5, 6A, 6B, 7F, 9V, 14, 19A, 19F, 23F
WHO Prequalification 2010 2016 2017 2020 2020
Price per dose $3.30 */$20.83 ** $2.90 * $3.05 * $3.50 * $2.00 *
Doses per fully immunized child 3 3 3 3 3
Indicative wastage rate 5% 8% 8% 5% 8%
Shelf-life 36 months at 2–8 °C 36 months at 2–8 °C 36 months at 2–8 °C 36 months at 2–8 °C 36 months at 2–8 °C
Cold chain volume per dose *** 12.6 cm3 3.9 cm3 2.7 cm3 17.0 cm3 3.7 cm3
Cost of cold room (per cm3) **** $0.0013 $0.0013 $0.0013 $0.0013 $0.0013
Handling open vials N.A.
Opened vials may be kept for
use in subsequent
immunization sessions (up to
28 days from the withdrawals
of the first injection if held at
2 to 8 °C)
Opened vials may be kept for use
in subsequent immunization
sessions (up to 28 days from the
withdrawals of the first injection
if held at 2 to 8 °C)
N.A.
Opened vials may be kept
for use in subsequent
immunization sessions (up
to 28 days from the
withdrawals of the first
injection if held at 2 to 8 °C)
N.A. = Not applicable; * Gavi-AMC price with procurement via UNICEF SD [25]; ** Government contract price of PCV13; *** According to Gavi’s latest report [24]; **** According to a
study by Parmar et al. and WHO Performance, Quality and Safety (PQS) standards [26,27].
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Up to now, there is no WHO position paper on a preference for a specific PCV-product, which
allows countries to make decisions for a product based on local epidemiological and programmatic
considerations. In the context of Indonesia, it is critical to estimate the economic impact of switch
from existing product/presentation of PCV (single-dose of PCV13) to new product/presentations of
PCV (multi-doses of PCV13, PCV10 A and B) as PCV is one of the most expensive vaccines in the
Expanded Program on Immunization (EPI) schedule. Since PCV recommendations vary worldwide [14],
this evidence is required to support vaccine introduction, optimize the impact of immunization and
warrant the government’s investment in the immunization program that is considered to be of great
public health value.
2. Interchangeability
PCVs have been used since 2000, with the licensure of PCV7. Currently, there are only two available
PCVs: PCV10 and PCV 13. PCV introduction in lower- and middle-income countries (LICs and MICs,
respectively) began in 2009 and has continued to increase over time. WHO has recommended that
PCVs should be administered in infants using a 2primary(p)+1 or 3p+0 schedule, with the primary
doses of each schedule administered at six months of age and the booster dose of the 2p+1 administered
at nine months of age or later. Intervals between doses are generally at least eight weeks apart for the
two primary doses in the 2p+1 schedule and at least four weeks apart for the 3p+0 schedule. Several
published studies have confirmed vaccine-specific data on immunogenicity, safety, effectiveness and
interchangeability, which demonstrated that both PCV 10 and PCV 13 exhibited grossly similar overall
characteristics and impacts on the outcomes with some specific differences [11,14,28–33].
2.1. Immunogenicity
Both PCV10 and PCV13 induce antibodies against the serotypes common across the two vaccines.
Although there are small differences in antibody response between the two products for the individual
serotypes, PCV10 and PCV13 have comparable, albeit not identical, immunogenicity. A recent
systematic review and meta-analysis on associations between geographic region and immune response
variations to PCVs showed a strong regional difference in the immune response [28]. Vaccinated
individuals in Asia, Africa and Latin America were considered to have higher geometric mean
concentrations (GMCs), compared to those in Europe and North America. Taking into account
anti-pneumococcal antibodies, the result of the meta-analysis showed that GMCs in all PCVs were
estimated to be 2.60 mg/mL (95% CI; 2.45–2.76 mg/mL), 2.30 mg/mL (95% CI; 2.21–2.39 mg/mL) and
1.60 mg/mL (95% CI; 1.54–1.65 mg/mL) after three doses of PCV7, PCV10 and PCV13, respectively [28].
Focusing on serotype 4 only, the study highlighted that PCV13 showed greater antibody responses
than PCV7 and PCV10 [28]. Additionally, a systematic literature review on interchangeability between
PCVs for pediatric use confirmed that four clinical trials showed that mixed schedules with a
PCV10-to-PCV13 switch at boosting or a PCV13-to-PCV10 switch during priming or at boosting were
similarly immunogenic with no apparent safety concerns [11].
2.2. Vaccine Safety
Both PCV10 and PCV13 have strong safety profiles. Next to immunogenicity evaluation,
a systematic review by Ciapponi et al. confirmed that there was no direct comparative information
available on the interchangeability among PCVs, but they have similar immunogenicity and safety [14].
Another systematic review assessed the reactogenicity and safety of mixed schedules [11]. The study
showed that switching from PCV13 to PCV 10 or vice versa at the time of boosting or from PCV13 to
PCV10 during priming did not appear to raise safety concerns [11].
2.3. Effectiveness
Effectiveness of PCVs against IPD among children under five years of age in Africa can be used to
explore the effectiveness of PCVs on IPD prevention in LICs and MICs [29]. The overall decline in IPD
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ranging from 31.7% to 80.1%. IPD caused by vaccine serotypes declined significantly at 35.0%–92.0%.
A much higher decline (55.0%–89.0%) was found in children under two years of age. Of all vaccine
serotypes, the relative proportions of serotypes 1, 5 and 19A doubled following vaccine roll-out [29].
In particular, a systematic review and meta-analysis of randomized controlled trials on the clinical
effectiveness of PCVs confirmed that PCV13, PCV10 and PCV7 could reduce the risk for IPD with
respective Odds Ratios (ORs) at 0.53 (95%CI; 0.36–0.78), 0.19 (95%CI; 0.11–0.33) and 0.37 (95%CI;
0.26–0.52) [30]. Focusing on the effectiveness of PCV13 against serotype 3 IPD, a study by Sings et al.
showed the effectiveness of PCV13 at 63.5% (95% CI; 37.3%–89.7%) [31]. In addition, when PCV13
was compared with previous PCV7 immunization, the incidence rate ratio (IRR) of hospitalization for
pneumonia in children was estimated to be 0.67 (95% CI; 0.62–0.74) [32]. Taking the cost-effectiveness
into account, Ciapponi et al. highlighted that PCV10 and PCV13 were consistently more cost-effective
than PCV7 [14]. Preliminary results of an economic evaluation study in Indonesia confirmed that
PCV13 was considered to be more cost-effective than PCV10 [33].
3. Implementation of PCV Immunization in MICs
In 2012, the WHO has updated the recommendation about PCV introduction for children under
two years old by giving prioritization to countries with high child mortality rates [34]. At this moment,
the majority of people live in MICs, where the majority of vaccine-preventable diseases occur [35,36].
Despite the fact that the number of MICs introducing PCV is steadily increasing [37], MICs may be
struggling with PCV implementation without external financial and technical support [38]. As a
consequence, a comprehensive strategy is required to massively reduce the burden of mortality and
morbidity due to pneumococcal disease in MICs within scarce budgets. To give an illustration about
the uptake of PCV in lower- and upper-middle-income countries (LMICs and UMICs, respectively),
a study by Tricarico et al. reported a significant difference in the uptake of PCV in LMICs (71%) and
UMICs (48%), which was mainly caused by an unsuccessful process of MICs graduation [39]. It can
be highlighted that once countries move from LICs into MICs or from LMICs into UMICs, financial
assistance (e.g., Gavi’s support) are gradually phased out. In these cases, MICs are forced to explore
the internal co-financing of vaccines.
The WHO reported PCV as one of the most expensive new vaccines to be included in national
immunization programs (NIPs) [34]. The price of PCV can vary over a wide range, from $3.30 per dose
(when purchased through Gavi) up to $159.58 per dose (the price of PCV13 in the private sector) [40].
In order to fully fund their NIPs, MICs should expand their fiscal space to introduce PCV, supported
with other activities, such as advocacy, technical assistance and training. As one of the MICs with
approximately 270 million population [41], Indonesia has not yet added PCV to its NIP.
To give an illustration of the situation in other MICs with high numbers of the population,
the Indian government has announced the possible introduction of PCV in a phased manner by
2017 [42]. In addition, the Chinese government has not yet included PCV in NIPs, but it is available at
immunization clinics for a fee [43]. Although substantial achievements have been made with other
immunization programs in MICs [44], the introduction of PCV and other new or under-used vaccines
(e.g., rotavirus, human papillomavirus and Japanese encephalitis vaccine) in these countries are still
lagging [45]. This situation might lead in at least 20% of the total population in MICs remaining
unprotected from these important pathogens, which corresponds with a missed opportunity to
dramatically reduce avoidable morbidity and mortality in countries where the majority of people live
and the majority of vaccine-preventable diseases occur [32,46]. Obviously, financial constraints reflect
an important obstacle.
4. Advance Market Commitment (AMC)
AMC is a legally binding commitment by donors to provide funds to subsidize the vaccine
purchase as an effort to reduce morbidity and mortality in low-resource countries [47]. This mechanism
was aimed to encourage the research and development of new vaccines, and accelerate the availability
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of new vaccines in those countries [48]. It has been envisaged that this mechanism was designed
both for early-stage (e.g., malaria, HIV/AIDS and tuberculosis vaccines) and late-stage development
(e.g., PCV, rotavirus and human papillomavirus vaccines). An AMC for vaccines was initiated by the
Center for Global Development in April 2005, which intended to create incentives for commercial
investments in research, development and manufacturing of new vaccines [49].
An AMC pilot for PCV was launched in June 2009 with a joint commitment of several countries,
such as Canada, Italy, Norway, the Russian Federation, the UK and the Bill and Melinda Gates
Foundation [50]. The World Bank led the pilot together with the UNICEF and the WHO by securing
$1.5 billion in AMC funding for the purchase of PCVs [51]. The Gavi Alliance, a public–private
partnership, was appointed as the AMC secretariat and has committed to supporting eligible countries
to purchase PCV through the AMC mechanism [52]. These eligible countries were allowed to apply
for subsidized PCVs, with a maximum vaccine price of $3.50 per dose [53]. To support this pilot,
the International Finance Facility for Immunization (IFFIm) provided $41.58 million to immunize
more than three million children and prevent more than 1.5 million deaths by 2020 [54]. Through the
Accelerated Vaccine Introduction (AVI) program that was initiated in 2008, Gavi aimed to broaden and
speed up access to PCVs [55]. In addition, the WHO has actively developed supporting programs to
help MICs on introducing PCV, such as through the Global Action Plan for the Prevention and Control
of Pneumonia and Diarrhoea (GAPPD) and the MIC Task Force, which aimed to reduce the number of
deaths due to pneumonia to be less than three children per 1000 live births by 2025 [32,56]. Furthermore,
the WHO Strategic Advisory Group of Experts on Immunization (SAGE) has noted a dramatic increase
in the implementation of new and under-utilized vaccines could potentially decrease morbidity and
mortality of vaccine-preventable diseases, including pneumococcal disease, as mentioned in the Global
Vaccine Action Plan (GVAP) of 2011–2020 [57,58].
To strengthen the implementation of AMC, the Pan American Health Organization (PAHO)
Revolving Fund launched initiatives to assist Latin American countries in negotiating a lower
cost of PCV through bulk procurement and provide technical assistance on supply management,
planning, procurement system, quality assurance, warehousing and distribution [59]. The Program for
Appropriate Technology in Health (PATH) has collaborated with private- and public-sector partners to
accelerate the introduction of PCVs by providing affordable vaccines for low-resource countries [60].
In addition, Médecins Sans Frontières (MSF) launched a global campaign in 2015 to slash the price of
PCV in MICs to be a maximum of $5 per child so that more children can be protected [39].
5. Impact of Switch Options on the Economics of PCV Introduction in Indonesia
Top-down cost estimation was applied to estimate the economic impact of switch options on
the introduction of PCV in Indonesia. This estimation was based on the cost of the current project in
two provinces, Nusa Tenggara Barat (NTB) and Bangka Belitung, and the expert judgment of those
involved in developing the cost estimation [22]. Applying this approach, the economic impact of
switch options due to parameters impacting vaccine cost (e.g., required doses, vaccine presentation,
indicative wastage rate, vaccine coverage, targeted area, safety stock, vaccine price and other additional
costs) and parameters impacting cold chain cost (e.g., cold chain volume per dose and cold chain cost
per cm3) were estimated and presented in a tabular format (see Table 2).
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contract price) Base value = $20.83 (Min = $18.94; Max = $61.00) [22]
PCV13—1 dose/vial (UNICEF price) * Base value = $3.30 (Lower = $2.48; Upper = $4.13) [61]
PCV13—4 doses/vial (UNICEF price) * Base value = $2.90 (Lower = $2.18; Upper = $3.63) [61]
PCV10 A—4 doses/vial (UNICEF price) * Base value = $3.05 (Lower = $2.29; Upper = $3.81) [61]
PCV10 B—5 doses/vial (UNICEF price) * Base value = $2.00 (Lower = $1.50; Upper = $2.50) [61]
Additional cost
Total additional cost ** Base value = 23.0% (Min = 19.5%, Max = 38.0%)
Vaccine wastage
Single-dose/vial Median = 5.0% (Min = 1%; Max = 10%) [26]
Multi-dose/vial Median = 7.0% (Min = 1%; Max = 27%) [26]
Safety stock
Total safety stock Base value = 5% (Min = 0%; Max = 10%)
Vaccine coverage
National coverage Base value = 90.8% (Min = 46%, Max = 100%) [25]
Cost of cold room
Cost per cm3 *** Base value = $0.0013 (Min = $0.0005; Max = $0.0022) [26,27]
IPD in children <1 years old
Incidence rate (per 100,000 population) 2911 (Range = 2265–3622) [62]
Risk reduction for IPD
PCV13 Odds Ratio = 0.53 (95% CI; 0.36–0.78) [30]
PCV10 A Odds Ratio = 0.19 (95% CI; 0.11–0.33) [30]
PCV10 B N.A.
N.A.: not applicable; * Lower and upper value: ± 25%; ** Base value (costs of forwarder, distribution, insurance and
service fee), Min (costs of the forwarder, distribution and insurance) and Max (costs of tax, import duty, forwarder,
distribution, insurance and service fee); *** Base value (cold room size: 10 m3), Min (cold room size: 40 m3) and Max
(cold room size: 5 m3).
This analysis was performed for the period of 2019–2024. Selected districts and provinces were
analyzed to implement PCV vaccination in Indonesia during that period. Several factors (e.g., the
incidence rate, coverage of routine immunization program and local government readiness) were
considered to prioritize districts and provinces on extending the introduction of vaccination. In 2019,
PCV was introduced in two provinces and five districts, as targeted by the Ministry of Health (MoH).
In 2020 and 2021, the introduction is targeted in four and six more provinces, respectively. In 2022
and 2023, it would be expanded in eight and 11 more provinces, respectively. In the end, nationwide
vaccination is targeted to be implemented in 2024 (see Table 3).
As the MoH has initiated to introduce PCV13 in 2017, we applied a situation that PCV13 would
be used in 2019–2024 as the base-case scenario. Since there is a regulation barrier to access Gavi-AMC
price through procurement via UNICEF SD, the use of single-dose PCV13 with the government contract
price was applied in 2019–2020. We assumed that the Gavi-AMC price for all PCVs can be accessed in
2021, as the starting year. In this analysis, three further scenarios were specifically compared with the
base-case scenario. In particular, the use of multi-dose PCV13, PCV10 A and PCV10 B with Gavi-AMC
price in 2021–2024 were considered in respective scenarios (see Table 4).
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Table 3. Targeted area of PCV introduction in Indonesia. Yellow, green and blue are for district,
province and national level, respectively.
2019 2020 2021 2022 2023 2024
District/Province District/Province District/Province District/Province District/Province District/Province
NTB NTB NTB NTB NTB Indonesia
Bangka Belitung Bangka Belitung Bangka Belitung Bangka Belitung Bangka Belitung
Kota Bogor Jawa Barat Jawa Barat Jawa Barat Jawa Barat
Kota Bekasi Jawa Timur Jawa Timur Jawa Timur Jawa Timur
Kota Surabaya DKI Jakarta DKI Jakarta DKI Jakarta
Gresik Banten Banten Banten
Sidoarjo DI Yogyakarta DI Yogyakarta DI Yogyakarta
Jawa Tengah Jawa Tengah Jawa Tengah
Lampung Lampung Lampung




Kepulauan Riau Kepulauan Riau
Sumatera Barat Sumatera Barat
Sumatera Utara Sumatera Utara





















Table 4. Alternative scenario of switch options on the introduction of PCV.
Scenario Year Vaccine Presentation Price
Base-case
2019–2023 PCV13 1 dose/vial Contract and Gavi-AMC price *
2024 PCV13 4 doses/vial Gavi-AMC price
Multi-dose PCV13
2019–2020 PCV13 1 dose/vial Contract price
2021–2024 PCV13 4 doses/vial Gavi-AMC price
Multi-dose PCV10 A
2019–2020 PCV13 1 dose/vial Contract price
2021–2024 PCV10 A 4 doses/vial Gavi-AMC price
Multi-dose PCV10 B
2019–2020 PCV13 1 dose/vial Contract price
2021–2024 PCV10 B 5 doses/vial Gavi-AMC price
* Government contract price: 2019–2020; Gavi-AMC price: 2021–2024.
Total required doses were calculated by considering targeted children under one year of age
in accordance with the vaccination schedule of PCV (2, 3 and 12 months old), vaccination coverage
of 91%, buffer stock of 5% and vaccine wastage of 5% (single-dose) and 7% (multi-dose) [23,25,26].
The economic impact of switch options was analyzed by taking into account the potential savings on
vaccine and cold chain costs from all scenarios, which were compared with the base-case scenario.
In this analysis, we applied the government contract price of $20.83 for the use of single-dose PCV13
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that was implemented in 2019–2020 [22]. For the Gavi-AMC vaccine, we estimated that there would
be additional costs of forwarder (2.5%), distribution (12%) and insurance (5%) [22]. In addition,
the UNICEF handling fee for new and under-used vaccines was estimated to be 3.5% for non-least
developed countries [63]. Applying Gavi-AMC prices of $3.30, $2.90, $3.05 and $2.00 for single-dose
PCV13, multi-dose PCV13, PCV10 A and PCV10 B, respectively [64], we estimated total vaccine cost
in 2019–2024 would be $308.76 million; $292.22 million; $301.01 million and $239.50 million for the
base-case and the respective scenarios of multi-dose PCV13, PCV10 A and PCV10 B. Considering
cold chain cost of $0.0013 per cm3 [26,27], we estimated total cold chain cost in 2019–2024 would
be $0.71 million; $0.33 million; $0.26 million and $0.32 million for the base-case and the respective
scenarios. In comparison with the base-case, we estimated total savings in 2019–2024 would be $16.91
million, $8.20 million and $69.65 million for the respective scenarios of multi-dose PCV13, PCV10 A
and PCV10 B (see Table 5).
Table 5. Total potential saving on vaccine and cold chain cost among all scenarios.
Cost 2019 2020 2021 2022 2023 2024 Total
Vaccine cost
Base case $24,916,689 $97,407,970 $35,218,736 $46,179,392 $54,966,739 $50,065,979 $308,755,504
Multi-dose PCV13 $24,916,689 $97,407,970 $30,949,799 $40,581,890 $48,304,104 $50,065,979 $292,226,430
Multi-dose PCV10 A $24,916,689 $97,407,970 $32,550,650 $42,680,953 $50,802,592 $52,655,598 $301,014,452
Multi-dose PCV10 B $24,916,689 $97,407,970 $21,344,689 $27,987,510 $33,313,175 $34,528,261 $239,498,294
Cold chain cost
Base case $19,590 $76,586 $142,124 $186,356 $221,817 $71,162 $717,636
Multi-dose PCV13 $19,590 $76,586 $43,991 $57,682 $68,658 $71,162 $337,669
Multi-dose PCV10 A $19,590 $76,586 $30,079 $39,440 $46,945 $48,658 $261,299
Multi-dose PCV10 B $19,590 $76,586 $41,359 $54,231 $64.550 $66,904 $323,220
Total saving
Multi-dose PCV13 $0 $0 $4,367,071 $5,726,176 $6,815,794 $0 $16,909,042
Multi-dose PCV10 A $0 $0 $2,780,131 $3,645,354 $4,339,018 −$2,567,15 $8,197,389
Multi-dose PCV10 B $0 $0 $13,974,813 $18,324,007 $21,810,831 $15,541,975 $69,651,626
Univariate sensitivity analyses were conducted to investigate the effects of the input parameters
on the savings. The result showed that vaccination coverage, vaccine price, vaccine wastage and
additional Gavi-AMC vaccine costs were considered to be the most influential parameters affecting the
savings in all scenarios (see Figure 1). Applying the incidence rate of IPD in children under one year
of age at 2911 per 100,000 population [62], and the effectiveness of PCV13 and PCV10 A on reducing
the risk for IPD at ORs of 0.53 (95% CI; 0.36–0.78) and 0.19 (95% CI; 0.11–0.33), respectively [30],
we estimated the potential averted incidence of IPD in children under one year of age during 2019–2024
at 246,164 and 105,587 for the respective scenarios of multi-dose PCV13 and PCV10 A (see Figure 2).
Due to the lack of data on the effectiveness of PCV10 B, we could not take a potential averted incidence
of IPD in children under one year of age into account for the last scenario.
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6. Programmatic Considerations
According to the WHO’s guideline on planning and managing vaccine introduction, several
switch activities and other supporting activities should be taken into account, such as decision-making
and switch request, planning and funding, vaccine procurement, vaccine distribution, human resources
and training, document production and distribution, cold chain, logistics and vaccine management,
surveillance and monitoring and evaluation [24,64].
In order to make a switch, several steps are required for evaluating the suitability of new product
or presentation with support from advisory bodies (e.g., National Immunization Technical Advisory
Group), developing a plan for the product/presentation switch (including activities, budget and timeline)
and submitting the switch application to Gavi. With respect to planning and funding issues, the Ministry
of Health (MoH) should establish a working group to coordinate switch activity in the country, develop
risk management strategy for an adverse event following immunization (AEFI) and secure funding for
activities not covered by Gavi or partners. To deal with vaccine procurement and distribution issues,
the stakeholder should carry out inventory of existing product/presentation, schedule the consumption
of old product/presentation before the introduction of new product/presentation, complete licensure
of new vaccine products/presentations and arrange a distribution plan for new product/presentation
to sub-national levels. In particular, training for health workers is required for dealing with the new
vaccine product/presentation and the use of existing presentations ahead of switch. To support this
training, there should be an updated document related to production and distribution (e.g., guidelines,
handbook for health workers, frequently asked questions, fact sheets, video, posters, pre- and
post-knowledge tests in local language) and reporting tools (e.g., vaccination logs, tools for wastage
calculation) [64].
To manage product/presentation switch (including cold chain and logistics), updated stock
management tools and more cold chain or dry storage space are critically required to include the new
product/presentation in central and intermediary levels. In the context of surveillance and monitoring,
the MoH should ensure adequate monitoring of vaccine wastage of the new product/presentation.
In particular, the National AEFI Expert Review Committee should be able to provide technical
guidance on real-world effectiveness causality assessment of AEFIs potentially related to the new
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product/presentation. To evaluate all related activities, there should be regular visits to local facilities
to confirm switch activities, to correct the use of new products/presentations and to gather lessons on
successes and challenges of the product/presentation switch (see Figure 3) [64].
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refers to the size of the vial in which the vaccine is supplied. Multi-dose vials can have 4, 5, or 10 doses
of vaccine in a vial while a single-dose vial has just one dose of the vaccine [26]. The manufacturing
costs in a multi-dose vial are spread over many doses and therefore they tend to cost less per dose
as compared to single-dose vials. Furthermore, multi-dose vials have lower cold chain costs. Hence,
they are also thought to be associated with higher wastage [66,67]. This study highlights the economic
value of switch options on the introduction of PCV in I donesia. Despite the fact that multi-dose
presentation has a higher indicative wastage rate (7%) than single-dose presentation (5%), the price of
multi-dose presentation vaccines is much lower than single-dose presentation. Our analysis suggests
a economic advantage to switch from single-dose into a multi-dose presentation. In terms of potential
savings, the option of single-dose PCV13 with the contract price in 2019–2020 that would be switched
into multi-dose PCV10 B with Gavi-AMC price in 2021–2024 resulted in the highest potential saving,
compared with other scenarios. This situation was caused by the fact that a multi-dose of PCV10
B, which was targeted to be available by the end of 2020, had the lowest estimated price compared
with other PCVs under Gavi-AMC price. Vaccination coverage, vaccine price, vaccine wastage a d
additional cost of the Gavi-AMC vaccine were considered to be the most influe tial parameter affecting
the savings in all scenarios. I particular, we briefly estimated potential averted incidence of IPD in
children under one year of age by taking into account the use of multi-dose PCV13 and PCV10 A,
respectively. We estimated a potential averted incidence of IPD in childre under one year of age during
2019–2024 would be 246,164 and 105,587 in both scenarios. Despite the result confirmed that PCV13
may provide an additional benefit, a more comprehensive economic evaluation study is required to
investigate further the comparison of cost-effectiveness values among all PCVs in Indonesia.
This is the first study to a alyze the economic impact of switch options on the introduction of
PCV in Indon sia. Nevertheless, several limitations a ply to this study. Firstly, in the absence f
country-specific data a ailabl on wast ge rate and cost of c ld chain, our estimation was based on
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global data according to Gavi’s report [24]. Due to a lack of this data, we were unable to identify the
cause of wastage and further analyze full costs of cold chain. However, if most of the wastage occurred
due to cold chain failures like inadequate infrastructure, power shortages and poor maintenance,
changing the vial size would not reduce this wastage [66]. To deal with this limitation, we took
into account these parameters in sensitivity analysis. Secondly, due to the lack of data on the
immunogenicity, safety and effectiveness of PCV10 B as the newest vaccine, part of our analysis
on these issues was focused on PCV13 and PCV10 A. Another limitation is that this study did not
consider the cost-effectiveness values of all PCVs that were compared. The cost-effectiveness values
of PCVs are associated with many factors, including the burden of disease, vaccine effectiveness,
indirect effects, vaccination coverage, vaccine price, delivery costs and schedule [68,69]. Although our
cost-consequence approach is sometimes considered less rigorous than other economic evaluations,
it is at the same time more versatile and practical, being able to offer clear and simple information.
Despite the inherent limitations discussed, the current work represents a preliminary initial overview
of switch options on the introduction of PCV in Indonesia, which is relevant with the current situation
since the government of Indonesia has committed to introducing PCV into its routine immunization
program with support from Gavi [70].
Several previous studies have indicated that PCV10 and PCV13 confer a comparable impact
in pneumococcal disease overall [71–73]. Both products exhibit effectiveness and impact on overall
disease and carriage. Nevertheless, there is no clear preference on using one product over the other in
most settings. Several benefits of vaccination may be offset by increased rates of disease caused by
non-covered serotypes. In settings with high burden attributable to serotype 3, PCV13 may have an
additional benefit over PCV10. Both vaccines have a good safety profile, with no serious side effects on
the individuals vaccinated [71–73]. The impact of PCV10 is similar to that of PCV13 across different
subgroups of age, gender, race and socioeconomic status [14]. Both vaccines exhibit comparable impact
and effectiveness overall on clinical outcomes. However, in settings of high serotypes 6A and 19A
burden, PCV13 and PCV10 B may lead to greater reductions than PCV10 A, as these serotypes are
contained in PCV13 and PCV10 B, and cross-protection from serotypes in PCV10 did not appear to
offer the same magnitude of benefit as those observed from using PCV13 and PCV 10 B.
Next to PCVs, other vaccines (e.g., diphtheria and tetanus toxoid combination vaccines,
hepatitis B, poliovirus, H. influenzae type b, measles-containing and rabies vaccines) are considered
interchangeable when administered under recommended indications [74–77]. The biggest challenge
on the interchangeability of PCVs is that their composition differs more than for other types of vaccines.
Despite the fact that a lot of previous studies recommended the completion of schedules with the
same vaccine in accordance with the manufacturers’ recommendations [2,8,9,78–81], there is a growing
number of countries that have switched from PCV13 to PCV 10 or vice versa, guided by and based
on epidemiological or programmatic considerations [13–17,82–86]. Several countries implemented a
gradual switch, in which a child’s schedule is completed with the vaccine given at first dose, while
other countries completed the series with the new vaccine regardless of doses have been given. A key
point that can be learned from the experience of Quebec, Canada is the use of a mixed schedule, which
was based on immunogenicity, protection against IPD, pneumonia and AOM, herd effects, safety,
cost-effectiveness, acceptability, feasibility and compliance [87]. In the epidemiological context of
Quebec, a schedule consisting of PCV10 only or a mixed PCV10/PCV13 schedule would be more
cost-effective than a PCV13 only schedule [87]. In addition, the government considered the high
acquisition cost of PCV13, the absence of conclusive evidence that one vaccine is superior in preventing
all pneumococcal diseases [7,78,88], the fact that PCV10 confers cross-protection against serotypes 6A
and 19A IPD [89–92], the limited protective effect of PCV13 on serotype 3 IPD [93–97], and the impact
of pertussis vaccination during pregnancy on the immunogenicity of a PCV13 infant schedule [98].
In the next couple of years, more studies are required to evaluate the interchangeability of PCVs
by taking into account effectiveness and impact against overall IPD as the main outcome from the
perspective of health economics. It is important to better understand the links between immunogenicity
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parameters and protection in real-life settings to enable interpretation of the results obtained in clinical
and economics studies. Even though the interchangeability data are still scarce, the available evidence
does not point to any major issues in switching from one PCV to another in NIPs. From a programmatic
point of view, this issue is crucial since it may enable decision-makers to more easily switch to the most
appropriate vaccine for their epidemiological or programmatic environment.
8. Conclusions
Our analysis suggests an economic advantage to switch from single-dose into a multi-dose
presentation. In terms of potential savings, the option of single-dose PCV13 with the contract price
in 2019–2020 that would be switched into multi-dose PCV10 B with Gavi-AMC price in 2021–2024
resulted in the highest potential saving, compared with other scenarios. Vaccination coverage, vaccine
price, vaccine wastage and additional cost of the Gavi-AMC vaccine were considered to be the most
influential parameter affecting the savings in all scenarios. Applying the effectiveness of PCV13 and
PCV10 A on reducing the risk for IPD, potential averted incidence of IPD in children under one year of
age during 2019–2024 would be 246,164 and 105,587 in both scenarios. Despite the result confirmed
that PCV13 may provide an additional benefit, a more comprehensive economic evaluation study is
required to investigate further the comparison of cost-effectiveness values among all PCVs in Indonesia.
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